Jamie L. Thomas
Research Subjects
Jamie L. Thomas has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Kevin Lin
The University of Texas MD Anderson Cancer Center
2 shared publications - Ahmed Zaki
Memorial Hermann Greater Heights
1 shared publication - Alex V. Stabler
Division of Pharmacy, The University of Texas MD Anderson Cancer Center
1 shared publication - Hiba Al Shaikhli
Department of Antimicrobial Stewardship, University of Mississippi Medical Center, Jackson, MS 39216, USA
1 shared publication - Khyati Amin
Department of Pharmacy, The University of Texas Medical Branch, Galveston, TX, USA
1 shared publication - Lauren Lee
The University of Texas Medical Branch
1 shared publication
Latest Publications
- Open Access
- 11 December 2025
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 39 (4) , 257-270
Significant Publications on Infectious Diseases Pharmacotherapy in 2024
Purpose: To provide a summarization of the most significant infectious diseases (ID) pharmacotherapy articles published in peer-reviewed literature in 2024. Summary: Members of the Houston Infectious Diseases Network (HIDN) nominated notable articles providing significant contributions to ID pharmacotherapy in 2024. Article nominations included those pertaining to general ID and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) pharmacotherapy in 2024. To aid selection of the most significant articles in 2024, a survey was created and distributed to members of the Society of Infectious Diseases Pharmacists (SIDP). Out of the 21 total articles nominated by HIDN/SIDP members, 19 pertained to general ID pharmacotherapy, and 2 had pertained to HIV/AIDS pharmacotherapy. Of the SIDP members who participated in the survey, 185 voted for the top 10 general ID pharmacotherapy articles and 46 votes were recorded for the top HIV/AIDS article. The most notable publications are summarized. Conclusion: This review provides a summary of the most recently published ID literature with aims to update clinicians on the current potential practice changing ID pharmacotherapy publications from 2024.
- 11 December 2025
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 39 (4) , 257-270
Open AccessSignificant Publications on Infectious Diseases Pharmacotherapy in 2024
Purpose: To provide a summarization of the most significant infectious diseases (ID) pharmacotherapy articles published in peer-reviewed literature in 2024. Summary: Members of the Houston Infectious Diseases Network (HIDN) nominated notable articles providing significant contributions to ID pharmacotherapy in 2024. Article nominations included those pertaining to general ID and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) pharmacotherapy in 2024. To aid selection of the most significant articles in 2024, a survey was created and distributed to members of the Society of Infectious Diseases Pharmacists (SIDP). Out of the 21 total articles nominated by HIDN/SIDP members, 19 pertained to general ID pharmacotherapy, and 2 had pertained to HIV/AIDS pharmacotherapy. Of the SIDP members who participated in the survey, 185 voted for the top 10 general ID pharmacotherapy articles and 46 votes were recorded for the top HIV/AIDS article. The most notable publications are summarized. Conclusion: This review provides a summary of the most recently published ID literature with aims to update clinicians on the current potential practice changing ID pharmacotherapy publications from 2024.
- 6 February 2025
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 38 (5) , 473-485
Significant Publications on Infectious Diseases Pharmacotherapy in 2023
Purpose: To provide a summarization of the most significant infectious diseases (ID) pharmacotherapy articles published in peer-reviewed literature in 2023. Summary: Members of the Houston Infectious Diseases Network (HIDN) nominated notable articles providing significant contributions to ID pharmacotherapy in 2023. Article nominations included those pertaining to general ID and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) pharmacotherapy. Out of the 31 articles nominated by HIDN members, 22 pertained to general ID pharmacotherapy, and 9 pertained to HIV/AIDS pharmacotherapy. To aid selection of the most notable articles of 2023, a survey was created and distributed to members of the Society of Infectious Diseases Pharmacists (SIDP). Of the 153 SIDP members who participated in the survey, there were 118 recorded votes for the top 10 general ID pharmacotherapy articles and 55 votes were recorded for the top HIV/AIDS article. The most notable publications are summarized. Conclusion: Advances in antimicrobial stewardship and infectious disease states continue to occur. Sustained growth in the publication of ID-related articles over the past year contributed to this review’s aim to aid clinicians in remaining current on potentially practice-changing ID pharmacotherapy publications from 2023. This review provides a summary of recently published ID literature, including emphasis on antimicrobial stewardship, appropriate treatment durations, new antimicrobials, and drug-resistant organisms.
- 6 February 2025
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 38 (5) , 473-485
Significant Publications on Infectious Diseases Pharmacotherapy in 2023
Purpose: To provide a summarization of the most significant infectious diseases (ID) pharmacotherapy articles published in peer-reviewed literature in 2023. Summary: Members of the Houston Infectious Diseases Network (HIDN) nominated notable articles providing significant contributions to ID pharmacotherapy in 2023. Article nominations included those pertaining to general ID and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) pharmacotherapy. Out of the 31 articles nominated by HIDN members, 22 pertained to general ID pharmacotherapy, and 9 pertained to HIV/AIDS pharmacotherapy. To aid selection of the most notable articles of 2023, a survey was created and distributed to members of the Society of Infectious Diseases Pharmacists (SIDP). Of the 153 SIDP members who participated in the survey, there were 118 recorded votes for the top 10 general ID pharmacotherapy articles and 55 votes were recorded for the top HIV/AIDS article. The most notable publications are summarized. Conclusion: Advances in antimicrobial stewardship and infectious disease states continue to occur. Sustained growth in the publication of ID-related articles over the past year contributed to this review’s aim to aid clinicians in remaining current on potentially practice-changing ID pharmacotherapy publications from 2023. This review provides a summary of recently published ID literature, including emphasis on antimicrobial stewardship, appropriate treatment durations, new antimicrobials, and drug-resistant organisms.